Likewise, synthetic GLP-1 receptor agonists are used successfully in the treatment of type-2 diabetes mellitus and to reduce overweight in obesity (for recent reviews, see Nauck and Meier [5] and Hussein et al. [6]). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.